Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial.
Deisseroth
A B
AB
University of Texas M.D. Anderson Cancer Center Division of Medicine.
Kavanagh
J
J
Champlin
R
R
D000293:Adolescent; D000328:Adult; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D018076:DNA, Complementary / Q000008:administration & dosage; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005240:Feasibility Studies; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects; D006412:Hematopoietic Stem Cells / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D010865:Pilot Projects; D012016:Reference Values; D012190:Retroviridae / Q000235:genetics*; D014161:Transduction, Genetic
D018076:DNA, Complementary; D017239:Paclitaxel